絞り込み

16506

広告

Bisphosphonates and other bone agents for breast cancer.

著者 O'Carrigan B , Wong MH , Willson ML , Stockler MR , Pavlakis N , Goodwin A
Cochrane Database Syst Rev.2017 Oct 30 ; 10():CD003474.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (31view , 0users)

Full Text Sources

Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast cancer and advanced breast cancer settings. This is an update of the review originally published in 2002 and subsequently updated in 2005 and 2012.
PMID: 29082518 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード